Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corteva (CTVA) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Corteva (CTVA) over the last 8 years, with Q4 2025 value amounting to $222.0 million.

  • Corteva's Capital Expenditures rose 2265.19% to $222.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $591.0 million, marking a year-over-year decrease of 100.5%. This contributed to the annual value of $591.0 million for FY2025, which is 100.5% down from last year.
  • Latest data reveals that Corteva reported Capital Expenditures of $222.0 million as of Q4 2025, which was up 2265.19% from $157.0 million recorded in Q3 2025.
  • In the past 5 years, Corteva's Capital Expenditures registered a high of $222.0 million during Q4 2025, and its lowest value of $94.0 million during Q1 2025.
  • In the last 5 years, Corteva's Capital Expenditures had a median value of $146.5 million in 2022 and averaged $148.0 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 7837.84% in 2021, then crashed by 3648.65% in 2025.
  • Quarter analysis of 5 years shows Corteva's Capital Expenditures stood at $160.0 million in 2021, then dropped by 9.38% to $145.0 million in 2022, then increased by 26.21% to $183.0 million in 2023, then fell by 1.09% to $181.0 million in 2024, then increased by 22.65% to $222.0 million in 2025.
  • Its Capital Expenditures stands at $222.0 million for Q4 2025, versus $157.0 million for Q3 2025 and $118.0 million for Q2 2025.